Back To: Home : Featured Technology : Reagents/Proteins

CLICK HERE FOR WHAT'S NEW IN:
 

Precision Antibody to provide antibody characterization for NCIís CPTC initiative
September 2010
SHARING OPTIONS:

COLUMBIA, Md. óIn late July, Precision Antibody announced that it will provide antibody and antigen characterization, including surface plasmon resonance (SPR) analysis, for the National Cancer Institute's (NCI) Clinical Proteomic Technologies for Cancer (CPTC) initiative. The CPTC aims to develop a standardized resource of high-quality, renewable reference antibodies generated against cancer-related proteins. The antibodies will be made available to proteomics researchers, along with characterization data and other information intended to support replication and standardization. The contract award was the result of a competitive bidding process among private companies that offer Biacore protein interaction analysis capabilities and was managed by SAIC-Fredrick, a wholly owned subsidiary of SAIC that operates the NCI's research center in Frederick, Md.
 

Back


PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.